All other branded bowel preps will be excluded from coverage on these three formularies. CLENPIQ is a ready-to-drink bowel prep for cleansing the colon as a preparation for colonoscopy and will gain exclusive preferred access through the Standard, Advanced Control, and Value formularies. ![]() With this new access, EUFLEXXA will be preferred by over 80% of lives managed by pharmacy benefit managers. ![]() “ We welcome this opportunity to broaden coverage for underserved patient communities and provide CVS Health and Aetna members with preferred access to EUFLEXXA and CLENPIQ in the U.S.”ĮUFLEXXA, used to relieve knee pain due to osteoarthritis, will gain exclusive preferred access for 37 million people through CVS Health. “Now more than ever, it’s critical for patients to have affordable access to the treatment options they need,” said Brent Ragans, President, Ferring Pharmaceuticals U.S. CVS Health is the largest pharmacy health care provider in the United States, providing access to a network of more than 64,000 pharmacies and managing the drug benefits for more than 103 million plan members, including six million Aetna lives. Parsippany, NJ – Decem– Beginning January 1, 2021, Ferring Pharmaceuticals will gain preferred access through CVS Health and Aetna formularies for EUFLEXXA ® (1% sodium hyaluronate) for the treatment of knee osteoarthritis (OA) pain and exclusive preferred access on three out of four formularies for CLENPIQ ® (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution for cleansing of the colon as a preparation for colonoscopy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |